Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Next Previous
Trial Profile

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Carcinoma; Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis; Salivary gland cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 29 Oct 2021 Interim results (data cut off: January 31, 2018; n=91) assessing the response to pexidartinib treatment in 6 cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity published in the Clinical Cancer Research
  • 11 Mar 2021 Status changed from active, no longer recruiting to completed.
  • 16 Nov 2020 Results of pooled analysis of data from 2 studies (NCT01004861 and NCT02371369) assessing the long term outcomes of Pexidartinib in tenosynovial giant cell tumors published in the Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top